From Wikipedia, the free encyclopedia

Cilnidipine (INN) is a calcium channel blocker. It is sold as 'Cilacar' in India as 5 mg and 10 mg tablets.

Cilnidipine is a dual blocker of L-type voltage-gated Ca2+ channels in vascular smooth muscle and N-type Ca2+ channels in sympathetic nerve terminals that supply blood vessels. However, the clinical benefits of cilnidipine and underlying mechanisms are incompletely understood.

Clinidipine is the new type of CaA accompanied with L type and N type Calcium - channel blocking function. It is jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved to come into market for the first time and used for high blood pressure treatment in 1995. CaA is another kind of rapidly developed angiomyocardiac followed b-blocking agent in the recent 10 years and widely used for high blood pressure, angina cordis, syndrome of myocardial ischemia, cerebrovascular disease and peripheral arterial disease clinically with the reputation of one of the five great progress in heart disease treatment. Compared with other CaA, clinidipine can act on the N type calcium-channel that existing sympathetic nerve end besides acting on L type calcium-channel that similar to most of the CaAs. With higher curative effect on lower the blood pressure and anti-atherosclerosis effect, the average effective rate of this product can be above 90% while the rate of side effect is below 10%. This product is the high blood pressure medicine with long effect, take it once per day and one grain per time for blood pressure control.

External links

• http://www.mcyy.com.cn/e-product2.asp
• http://www.ncbi.nlm.nih.gov/pubmed/12011649
• http://www.nature.com/bjp/journal/v147/n1/abs/0706450a.html